Portfolio Lab

Tema Oncology ETF

  • ETF
  • Ticker CANC
  • NASDAQ

Performance, volatility and drawdowns of Tema Oncology ETF since 09/2021, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

CANCGlobal equities (VT)

$10,000 grew to $6,600. Global equities (VT): $14,653.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −97.5% in 04/2023, measured from the peak in 10/2021. The old peak has not been reached again yet.

Annual returns

Best year 2023 at +510.4%, weakest 2022 at −85.3%. 2 of 4 full years were positive. * partial year.

Similar ETFs

Frequently asked questions

How has CANC performed since 09/2021?

$10,000 grew to $6,300 by 20 Nov 2026, which is −8.6% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is CANC?

Volatility was 177.7% per year, measured on monthly returns. The largest decline from a peak was −97.5%, with the low in 04/2023.

How does CANC compare with a broad equity ETF?

Over the same period Global equities (VT) returned +8.8% per year at 15.3% volatility, CANC returned −8.6% at 177.7%. The correlation of monthly returns was 0.01; 1 would mean they moved in lockstep.

What does CANC hold?

CANC holds 58 positions. The largest are Revolution Medicines Inc, Eli Lilly & Co and Cogent Biosciences Inc; the 10 largest together make up 40.7% of the fund (holdings as of 31 Aug 2026, according to the fund's filing with the SEC).

Which currency are the figures in?

In US dollars, the currency of the US listing.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Tema Oncology ETF (CANC): Return and risk | Portfolio Lab